Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform

SPR741 Phase 1b Drug-Drug Interaction Study and SPR206 IND-enabling Studies Provide Support for Further Clinical Development Phase 1b data demonstrates pharmacokinetic compatibility and tolerability of SPR741 when co-administered with b -lactam antibiotics and continues to build on safety profile

READ FULL TEXT

Leave a Reply

Your email address will not be published.